Clinical Trial

Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1)

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated June 10, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study will employ a randomized, parallel-group design with two-stage randomization. After an initial brief screen for basic eligibility, participants will be randomized (within site) to either Remote (R) or In-Person (IP) Intake Groups. During the Intake, detailed consent and eligibility assessment will be completed. Participants who are eligible at the Intake will be randomized (within site and Intake Group) to R or IP Treatment and Assessment Groups. Participants will be followed for 3 months.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-11
Trial Details
NCT Number NCT06822049
Lead Sponsor State University of New York at Buffalo
Collaborators: Medical University of South Carolina, University of Pennsylvania, University of Alabama at Birmingham, National Center for Advancing Translational Sciences (NCATS), Abramson Cancer Center at Penn Medicine, Wake Forest University Health Sciences
Conditions Remote vs. In-Person, Remote Visits, In-person Visits
Enrollment 200 participants
Start Date 2025-03-10
Primary Completion 2026-07-31 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-06-10